Takeda Pharmaceutical (TAK) Projected to Post Earnings on Thursday

Key Points

• Takeda Pharmaceutical is expected to announce its Q2 2026 earnings on October 30, 2025, with forecasts of $0.46 earnings per share and $8.0077 billion in revenue.
• The company reported $0.52 earnings per share for Q2 2025, surpassing analyst estimates, but its revenue of $7.45 billion fell short of expectations.
• Analysts have mixed ratings on Takeda's stock, with one Buy, one Hold, and one Sell, leading to an average rating of "Hold".

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) is projected to announce its Q2 2026 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $0.46 per share and revenue of $8.0077 billion for the quarter. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS.Investors can check the company's upcoming Q2 2026 earningsummary page for the latest details on the call scheduled for Thursday, October 30, 2025 at 6:00 AM ET.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The firm had revenue of $7.45 billion during the quarter, compared to analysts' expectations of $7.96 billion. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Up 0.1%

TAK opened at $14.13 on Thursday. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The firm has a 50 day moving average price of $14.78 and a 200-day moving average price of $14.74. Takeda Pharmaceutical has a twelve month low of $12.80 and a twelve month high of $15.69. The stock has a market capitalization of $44.95 billion, a price-to-earnings ratio of 47.08 and a beta of 0.21.

Institutional Trading of Takeda Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the company. Sivia Capital Partners LLC purchased a new stake in shares of Takeda Pharmaceutical in the second quarter worth $351,000. Focus Partners Wealth boosted its position in shares of Takeda Pharmaceutical by 4.1% during the first quarter. Focus Partners Wealth now owns 82,738 shares of the company's stock worth $1,230,000 after acquiring an additional 3,239 shares during the last quarter. Vident Advisory LLC boosted its position in shares of Takeda Pharmaceutical by 277.8% during the second quarter. Vident Advisory LLC now owns 78,329 shares of the company's stock worth $1,211,000 after acquiring an additional 57,597 shares during the last quarter. Orion Porfolio Solutions LLC boosted its position in shares of Takeda Pharmaceutical by 30.3% during the second quarter. Orion Porfolio Solutions LLC now owns 56,436 shares of the company's stock worth $873,000 after acquiring an additional 13,118 shares during the last quarter. Finally, Evergreen Capital Management LLC boosted its position in shares of Takeda Pharmaceutical by 27.5% during the second quarter. Evergreen Capital Management LLC now owns 39,523 shares of the company's stock worth $611,000 after acquiring an additional 8,520 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TAK has been the subject of a number of research reports. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Takeda Pharmaceutical in a report on Tuesday, October 14th. Zacks Research cut shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.